Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ron Dagan

Showing results (311-320 of 367) with videos related to

Pageof 37
Sort By:
Emerging Infectious Diseases|April 23, 2014
Persistence and complex evolution of fluoroquinolone-resistant Streptococcus pneumoniae cloneDebby Ben-David, Mitchell J Schwaber, Amos Adler, et al.
Vaccine|February 25, 2023
Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2)Thomas Benfield, Mika Rämet, Piero Valentini, et al.
Scientific Reports|March 14, 2019
Streptococcus pneumoniae Cell Wall-Localized Trigger Factor Elicits a Protective Immune Response and Contributes to Bacterial Adhesion to the HostAviad Cohen, Shani Troib, Shahar Dotan, et al.
Plos One|September 1, 2016
Natural Killer Receptor 1 Dampens the Development of Allergic Eosinophilic Airway InflammationShirin Elhaik Goldman, Itay Moshkovits, Avishai Shemesh, et al.
The Pediatric Infectious Disease Journal|August 28, 2007
Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trialRon Dagan, Jacob Amir, Gilat Livni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2010
Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysisDaniel M Weinberger, Zitta B Harboe, Elisabeth A M Sanders, et al.
The Pediatric Infectious Disease Journal|November 21, 2002
Multinational study of pneumococcal serotypes causing acute otitis media in childrenWilliam P Hausdorff, Greg Yothers, Ron Dagan, et al.
Vaccine|September 23, 2022
A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)Natalie Banniettis, Jacek Wysocki, Leszek Szenborn, et al.
Plos One|September 3, 2011
The natural cytotoxicity receptor 1 contribution to early clearance of Streptococcus pneumoniae and to natural killer-macrophage cross talkShirin Elhaik-Goldman, Daniel Kafka, Rami Yossef, et al.
Vaccine|April 12, 2023
Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (Synflorix<sup>TM</sup> and Prevenar13<sup>TM)</sup>) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-labelled randomized controlled trial in Indian childrenAnand Kawade, Girish Dayma, Aditi Apte, et al.
Pageof 37

Showing results (311-320 of 367) with videos related to

Sort By:
Pageof 37
Emerging Infectious Diseases|April 23, 2014
Persistence and complex evolution of fluoroquinolone-resistant Streptococcus pneumoniae cloneDebby Ben-David, Mitchell J Schwaber, Amos Adler, et al.
Vaccine|February 25, 2023
Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2)Thomas Benfield, Mika Rämet, Piero Valentini, et al.
Scientific Reports|March 14, 2019
Streptococcus pneumoniae Cell Wall-Localized Trigger Factor Elicits a Protective Immune Response and Contributes to Bacterial Adhesion to the HostAviad Cohen, Shani Troib, Shahar Dotan, et al.
Plos One|September 1, 2016
Natural Killer Receptor 1 Dampens the Development of Allergic Eosinophilic Airway InflammationShirin Elhaik Goldman, Itay Moshkovits, Avishai Shemesh, et al.
The Pediatric Infectious Disease Journal|August 28, 2007
Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trialRon Dagan, Jacob Amir, Gilat Livni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2010
Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysisDaniel M Weinberger, Zitta B Harboe, Elisabeth A M Sanders, et al.
The Pediatric Infectious Disease Journal|November 21, 2002
Multinational study of pneumococcal serotypes causing acute otitis media in childrenWilliam P Hausdorff, Greg Yothers, Ron Dagan, et al.
Vaccine|September 23, 2022
A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)Natalie Banniettis, Jacek Wysocki, Leszek Szenborn, et al.
Plos One|September 3, 2011
The natural cytotoxicity receptor 1 contribution to early clearance of Streptococcus pneumoniae and to natural killer-macrophage cross talkShirin Elhaik-Goldman, Daniel Kafka, Rami Yossef, et al.
Vaccine|April 12, 2023
Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (Synflorix<sup>TM</sup> and Prevenar13<sup>TM)</sup>) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-labelled randomized controlled trial in Indian childrenAnand Kawade, Girish Dayma, Aditi Apte, et al.
Pageof 37